Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients

BACKGROUND: The advent of targeted therapy for cancer treatment has brought about a paradigm shift in the clinical management of human malignancies. Agents such as erlotinib used for EGFR-mutant non-small cell lung cancer or imatinib for chronic myeloid leukemia, for instance, lead to rapid tumor re...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lin L., Li, Fei, Pao, William, Michor, Franziska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633116/
https://www.ncbi.nlm.nih.gov/pubmed/26536620
http://dx.doi.org/10.1371/journal.pone.0141665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633116/
https://www.ncbi.nlm.nih.gov/pubmed/26536620
http://dx.doi.org/10.1371/journal.pone.0141665

Ejemplares similares